BlackRock Fund Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

BlackRock Fund Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$78M	Buy	2,704,309 +150,022	+6%	+$3.97M	0.01%	1388
2016 Q3	$81.3M	Buy	2,554,287 +214,275	+9%	+$7.26M	0.02%	1235
2016 Q2	$76M	Sell	2,340,012 -1,209,066	-34%	-$40.5M	0.02%	1200
2016 Q1	$99.2M	Buy	3,549,078 +349,519	+11%	+$7.62M	0.02%	962
2015 Q4	$114M	Sell	3,199,559 -191,052	-6%	-$6.73M	0.03%	858
2015 Q3	$112M	Buy	3,390,611 +183,527	+6%	+$7.64M	0.03%	818
2015 Q2	$134M	Sell	3,207,084 -69,296	-2%	-$2.68M	0.03%	763
2015 Q1	$107M	Buy	3,276,380 +84,595	+3%	+$2.91M	0.03%	940
2014 Q4	$101M	Buy	3,191,785 +264,873	+9%	+$7.51M	0.03%	940
2014 Q3	$72.5M	Sell	2,926,912 -9,031	-0.3%	-$211K	0.02%	1093
2014 Q2	$66.3M	Sell	2,935,943 -131,727	-4%	-$2.75M	0.02%	1210
2014 Q1	$74.6M	Buy	3,067,670 +276,101	+10%	+$6.98M	0.02%	1086
2013 Q4	$69.8M	Sell	2,791,569 -1,133	-0%	-$26.7K	0.02%	1142
2013 Q3	$76.7M	Buy	2,792,702 +371,913	+15%	+$7.77M	0.03%	970
2013 Q2	$43.9M	Buy	+2,420,789	New	+$33.3M	0.02%	1313

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BlackRock Fund Advisors's ACAD Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 5.9% in Q4 2016, buying an estimated $3.97M and bringing the position to 2,704,309 shares worth $78M. The position accounts for 0.01% of the portfolio, ranked #1388.

BlackRock Fund Advisors first reported a position in ACAD in Q2 2013 and has held it in 15 quarters since. The position peaked at $134M in Q2 2015. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

BlackRock Fund Advisors held 2,704,309 shares of Acadia Pharmaceuticals worth $78M as of Q4 2016.
BlackRock Fund Advisors bought 150,022 Acadia Pharmaceuticals shares in Q4 2016, an estimated $3.97M.
Acadia Pharmaceuticals made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1388 holding.
BlackRock Fund Advisors first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Acadia Pharmaceuticals position peaked at $134M in Q2 2015.
225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.